DiaMedica Therapeutics Inc. – NASDAQ:DMAC
DiaMedica Therapeutics stock price today
$6.17
+0.75
+14.05%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
DiaMedica Therapeutics stock price monthly change
+55.91%
month
DiaMedica Therapeutics stock price quarterly change
+55.91%
quarter
DiaMedica Therapeutics stock price yearly change
+87.20%
year
DiaMedica Therapeutics key metrics
Market Cap | 229.41M |
Enterprise value | 38.57M |
P/E | -3.06 |
EV/Sales | N/A |
EV/EBITDA | -2.83 |
Price/Sales | N/A |
Price/Book | 1.34 |
PEG ratio | -0.15 |
EPS | -0.56 |
Revenue | N/A |
EBITDA | -26.04M |
Income | -19.26M |
Revenue Q/Q | N/A |
Revenue Y/Y | 34549.43% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDiaMedica Therapeutics stock price history
DiaMedica Therapeutics stock forecast
DiaMedica Therapeutics financial statements
| Jun 2023 | 0 | -4.47M | |
|---|---|---|---|
| Sep 2023 | 0 | -4.47M | |
| Dec 2023 | 30.83M | -5.16M | -16.74% |
| Mar 2024 | 0 | -5.15M |
| Sep 2025 | 0 | -10.24M | |
|---|---|---|---|
| Oct 2025 | 0 | -10.24M | |
| Dec 2025 | 0 | -8.72M | |
| Dec 2025 | 0 | -7.97M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 62050000 | 2.30M | 3.72% |
|---|---|---|---|
| Sep 2023 | 58139000 | 2.51M | 4.32% |
| Dec 2023 | 54160000 | 3.10M | 5.73% |
| Mar 2024 | 49260000 | 2.91M | 5.91% |
| Jun 2023 | -5.03M | -28.12M | 36.85M |
|---|---|---|---|
| Sep 2023 | -4.79M | 1.19M | -6K |
| Dec 2023 | -3.57M | 6.39M | -489.33K |
| Mar 2024 | -6.65M | 4.20M | -1K |
DiaMedica Therapeutics alternative data
| Sep 2023 | 16 |
|---|---|
| Oct 2023 | 16 |
| Nov 2023 | 16 |
| Dec 2023 | 16 |
| Jan 2024 | 16 |
| Feb 2024 | 16 |
| Apr 2024 | 18 |
| May 2024 | 18 |
| Jun 2024 | 18 |
| Jul 2024 | 18 |
DiaMedica Therapeutics other data
2.27%
-5.96%
of DMAC is owned by hedge funds
14
-11
472.00K
-1.23M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 20000 | 0 |
| Jun 2024 | 2400000 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 15 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Dietrich John Pauls MBA (1971) Pres, Chief Executive Officer & Director | $687,580 |
| Dr. Harry W. Alcorn Jr., Pharm.D. (1956) Senior Vice President of Clinical Operations | $389,930 |
Mr. Scott B. Kellen C.A. (1965) Chief Financial Officer & Company Sec. | $370,160 |
-
What's the price of DiaMedica Therapeutics stock today?
One share of DiaMedica Therapeutics stock can currently be purchased for approximately $6.17.
-
When is DiaMedica Therapeutics's next earnings date?
Unfortunately, DiaMedica Therapeutics's (DMAC) next earnings date is currently unknown.
-
Does DiaMedica Therapeutics pay dividends?
No, DiaMedica Therapeutics does not pay dividends.
-
How much money does DiaMedica Therapeutics make?
DiaMedica Therapeutics has a market capitalization of 229.41M.
-
What is DiaMedica Therapeutics's stock symbol?
DiaMedica Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "DMAC".
-
What is DiaMedica Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of DiaMedica Therapeutics?
Shares of DiaMedica Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are DiaMedica Therapeutics's key executives?
DiaMedica Therapeutics's management team includes the following people:
- Mr. Dietrich John Pauls MBA Pres, Chief Executive Officer & Director(age: 54, pay: $687,580)
- Dr. Harry W. Alcorn Jr., Pharm.D. Senior Vice President of Clinical Operations(age: 69, pay: $389,930)
- Mr. Scott B. Kellen C.A. Chief Financial Officer & Company Sec.(age: 60, pay: $370,160)
-
How many employees does DiaMedica Therapeutics have?
As Jul 2024, DiaMedica Therapeutics employs 18 workers.
-
When DiaMedica Therapeutics went public?
DiaMedica Therapeutics Inc. is publicly traded company for more then 13 years since IPO on 3 Aug 2012.
-
What is DiaMedica Therapeutics's official website?
The official website for DiaMedica Therapeutics is diamedica.com.
-
Where are DiaMedica Therapeutics's headquarters?
DiaMedica Therapeutics is headquartered at Two Carlson Parkway, Minneapolis, MN.
-
How can i contact DiaMedica Therapeutics?
DiaMedica Therapeutics's mailing address is Two Carlson Parkway, Minneapolis, MN and company can be reached via phone at +7 636126755.
DiaMedica Therapeutics company profile:
DiaMedica Therapeutics Inc.
diamedica.comExchange:
NASDAQ
Full time employees:
18
Industry:
Biotechnology
Sector:
Healthcare
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Two Carlson Parkway
Minneapolis, MN 55447
Minneapolis, MN 55447
CIK: 0001401040
ISIN: CA25253X2077
CUSIP: 25253X207
